 WESTMER, Colo., Nov. 23, 2020 GLOBE NEWSWIRE -- ARCA biopharma, Inc. Nasdaq: ABIO, a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Food and Drug Administration FDA has designated as a Fast Track development program the investigation of AB201 as a potential treatment for COVID-19. The Company intends to initiate a Phase 2b clinical trial ASPEN-COVID-19 of AB201 in approximately 100 patients hospitalized with COVID-19 in December 2020, with topline trial data anticipated in the second quarter of 2021. 